Floatz logo

e7 tcr-t cells

Oropharynx Cancer

Christian HinrichsCell therapyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Oropharynx Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Turnstone Biologics, Corp.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Loren Mell, MD
Phase 2CCC
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)-
VM Oncology, LLC
Phase 1/2CCC
Tbio-6517
Turnstone Biologics, Corp.
Phase 1CC

Same molecule, other indications

e7 tcr-t cells is also rated in:

cervical carcinomaDormant
B
Indicative ·
60 / 100
View asset →
vulva cancerDormant
B
Indicative ·
60 / 100
View asset →
penile cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →